# Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

Study · id `cardio:ct-nct07800572` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07800572](<https://clinicaltrials.gov/study/NCT07800572>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07800572

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.

## Technical summary

Registry record NCT07800572. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-06 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 204 participants (planned count; ClinicalTrials.gov record NCT07800572, source copy `cardio:ctgov-nct07800572-2026-10-13`, retrieved 2026-10-26)
- Started: 2026-09-06 (actual) (ClinicalTrials.gov record NCT07800572, source copy `cardio:ctgov-nct07800572-2026-10-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07800572, source copy `cardio:ctgov-nct07800572-2026-10-13`, retrieved 2026-10-26)
- Completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT07800572, source copy `cardio:ctgov-nct07800572-2026-10-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07800572, source copy `cardio:ctgov-nct07800572-2026-10-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07800572-2026-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Anisodine Hydrobromide
- Intervention (Drug): Anisodine Hydrobromide Placebo
- Lead sponsor: Capital Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Capital Medical University (`cardio:org-capital-medical-university`)

## Provenance

Content hash: f0c31db81ec4a9e173a4413aa33c18b12518a71bce1358f60bfc98c3a525e83f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
